Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 499-506

  Benaboud, Sihem ^a,b   Urien, Saïk ^a,b   Thervet, Eric ^c   Prié, Dominique ^d   Legendre, Christophe ^d   Souberbielle, Jean Claude ^d   Hirt, Déborah ^a,b,e   Friedlander, Gérard ^d   Treluyer, Jean Marc ^a,b,e   Courbebaisse, Marie ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Paris Descartes University   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e Institut Cochin   (France)

Author keywords

25 Hydroxy vitamin D; Cholecalciferol; Kidney transplant patients; Optimal dosing; Pharmacokinetic modeling; Vitamin D insufficiency

Indexed keywords

CALCIFEDIOL; COLECALCIFEROL;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GRAFT RECIPIENT; HUMAN; INTENSIVE CARE; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN METABOLISM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHOLECALCIFEROL; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; KIDNEY TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84877138997     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1378-3     Document Type: Article

References (21)

1. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, Bischoff-Ferrari HA, Cavalier E, Ebeling PR, Fardellone P, Gandini S, Gruson D, Guérin AP, Heickendorff L, Hollis BW, Ish-Shalom S, Jean G, von Landenberg P, Largura A, Olsson T, Pierrot-Deseilligny C, Pilz S, Tincani A, Valcour A, Zittermann A (2010) Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev 9(11):709-715
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911-1930
3. Vieth R (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69(5):842-856
4. Courbebaisse M, Thervet E, Souberbielle JC, Zuber J, Eladari D, Martinez F, Mamzer-Bruneel MF, Urena P, Legendre C, Friedlander G, Prié D (2009) Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 75(6):646-651
5. Stavroulopoulos A, Cassidy MJD, Porter CJ, Hosking DJ, Roe SD (2007) Vitamin D status in renal transplant recipients. Am J Transplant 7(11):2546-2552
6. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, Pineau T, Saric J, Navarro F, Maurel P, Vilarem MJ (2005) Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 115(1):177-186
7. Akeno N, Matsunuma A, Maeda T, Kawane T, Horiuchi N (2000) Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol 164(3):339-348
8. Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Jüppner H, Wolf M (2006) Post-transplant hypophosphatemia: tertiary "hyper-phosphatoninism"? Kidney Int 70(8):1486-1494
9. Courbebaisse M, Souberbielle JC, Thervet E (2010) Potential nonclassical effects of vitamin D in transplant recipients. Transplantation 89(2):131-137
10. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4(6):905-913
11. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador JT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 77(4):299-311
12. Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D (2005) A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 79(1):108-115
13. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G (1995) Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 6(2):257-263
14. SourceForge. Available at: http://wfn.sourceforge.net/. Accessed 13 June 2012
15. Parke J, Holford NH, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59(1):19-29
16. Comets E, Brendel K, Mentré F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90(2):154-166
17. Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558-569
18. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266-281
19. Mawer EB, Schaefer K, Lumb GA, Stanbury SW (1971) The metabolism of isotopically labelled vitamin D3 in man: the influence of the state of vitamin D nutrition. Clin Sci 40(1): 39-53
20. Batchelor AJ, Watson G, Compston JE (1982) Changes in plasma half-life and clearance of 3 H-25-hydroxyvitamin D3 in patients with intestinal malabsorption. Gut 23(12):1068-1071
21. Clements MR, Davies M, Hayes ME, Hickey CD, Lumb GA, Mawer EB, Adams PH (1992) The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) 37(1): 17-27